

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

## PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 88686

**Title:** N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03724101

**Position:** Editorial Board

Academic degree: FACE, FRCP, MD, MRCP

**Professional title:** Professor

Reviewer's Country/Territory: India

Author's Country/Territory: China

Manuscript submission date: 2023-10-05

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2023-11-29 00:47

Reviewer performed review: 2023-12-02 00:28

Review time: 2 Days and 23 Hours

	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C:
Scientific quality	Good
	[ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	<ul> <li>[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair</li> <li>[ ] Grade D: No creativity or innovation</li> </ul>



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-399-1568 E-mail: office@baishideng.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	<ul> <li>[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair</li> <li>[ ] Grade D: No scientific significance</li> </ul>
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	<ul> <li>[ ] Accept (High priority)</li> <li>[ ] Accept (General priority)</li> <li>[ Y] Minor revision</li> <li>[ ] Major revision</li> <li>[ ] Rejection</li> </ul>
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous       [] Onymous         Conflicts-of-Interest: [] Yes       [Y] No

## SPECIFIC COMMENTS TO AUTHORS

Was the primary objective only for early stage? Was the study adequately powered to evaluate the early stage PDAC, given that it included only 51 out of 88 subjects? Why other stages were included ? What were the faetures of false negative cases?